SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

barzolvolimab

CLDX·Celldex Therapeutics, Inc.
BULLISH
Drug Impact Rating4/10
Trial phase
Phase 3 (CSU); Phase 3 (ColdU/SD); Phase 2 (Atopic Dermatitis)
Time to market
BLA submission planned for 2027, followed by a standard 12-month FDA review cycle. If approved, potential launch in late 2028 or early 2029 for CSU.
Why 4/10
The Phase 3 CSU topline binary (Sept 22, 2026) has already passed with positive results. The next hard catalyst is the BLA submission planned for 2027, but no specific date has been given, and there is no PDUFA date or pivotal readout scheduled with a specific date within the next ~12 months. The drug is the primary value driver for Celldex, but without a dated near-term binary, the impact score is capped at 4.
Actionable Insight BULLISH

The Phase 3 CSU binary is behind the stock (positive Sept 2026). The next major catalyst is the BLA submission planned for 2027, which would trigger a ~12-month FDA review cycle. Watch for the BLA filing announcement and any Phase 2 atopic dermatitis data readout, which could provide additional pipeline optionality. The stock trades at ~$30 with a mean analyst target of $63, reflecting the wide gap between current price and potential approval value.

Price Chart

Loading chart...

Executive Summary

Barzolvolimab (CDX-0159) is Celldex Therapeutics' lead asset, a humanized monoclonal antibody that depletes mast cells by blocking the KIT receptor. In September 2026, it delivered positive Phase 3 topline results in chronic spontaneous urticaria (CSU), meeting primary and all key secondary endpoints across two trials (EMBARQ-CSU1 and EMBARQ-CSU2). The company plans to submit a Biologics License Application (BLA) to the FDA in 2027. Beyond CSU, barzolvolimab is in a Phase 3 registrational program for cold urticaria/symptomatic dermographism and a Phase 2 trial in atopic dermatitis, though a Phase 2 prurigo nodularis study failed in July 2026 and was discontinued. With 19 of 19 analysts rating it Buy or Strong Buy and a mean price target of $63 (111% upside from ~$30), the drug is the primary value driver for Celldex, but the next major binary catalyst (BLA submission/approval) is not specifically dated.

How It Works

Barzolvolimab is a humanized monoclonal antibody that targets and depletes mast cells, a type of immune cell that drives allergic and inflammatory reactions. It works by binding to the KIT receptor on mast cells and blocking its activation, which is essential for mast cell survival and function. By eliminating these overactive immune cells, the drug can stop the hives, itching, and swelling that characterize chronic urticaria (hives) and other mast cell-driven diseases. Unlike existing therapies that block individual inflammatory signals, barzolvolimab removes the source cells themselves, which may explain its durable effects that persist months after treatment stops.

Trial Status

Phase 3 CSU trials (EMBARQ-CSU1 and EMBARQ-CSU2) met primary and all key secondary endpoints in September 2026; 52-week data still being collected. Phase 3 ColdU/SD trial initiated December 2025, ongoing. Phase 2 atopic dermatitis trial initiated December 2024, ongoing. Phase 2 prurigo nodularis trial failed in July 2026 and was discontinued. Phase 2 eosinophilic esophagitis trial met its primary endpoint but the program was dropped in August 2025.

The Two-Sided Case

▲ Bull Case6
Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials met primary and all key secondary endpoints at 12 weeks with both dosing regimens (150mg Q4W and 300mg Q8W), described by management as 'best-in-disease' results.
Barzolvolimab's novel mechanism (KIT receptor antagonist depleting mast cells) works independently of IgE levels, potentially addressing patients who fail or are not eligible for Xolair.
Long-term data showed durable off-treatment responses: up to 64% of patients maintained angioedema improvement 7 months after stopping treatment (Week 76).
Analyst consensus is overwhelmingly positive: 19 analysts rate it Strong Buy or Buy, with a mean price target of $63.07 (111% upside from ~$30).
Institutional accumulation is strong: BlackRock, Goldman Sachs, T. Rowe Price, and Baker Bros. all added or doubled positions in Q2 2026, and Fisher Asset Management added in Q3 2026.
The pipeline extends beyond CSU into cold urticaria/symptomatic dermographism (Phase 3) and atopic dermatitis (Phase 2), offering multiple shots on goal.
▼ Bear Case5
Phase 2 prurigo nodularis trial failed to meet its primary endpoint in July 2026, and the program was discontinued, highlighting clinical risk in indication expansion.
Phase 2 eosinophilic esophagitis program was dropped in August 2025 despite meeting its primary endpoint, suggesting the risk/benefit profile may limit the addressable market.
The stock fell over 20% on Phase 3 CSU topline day despite positive results, indicating the market may have priced in efficacy or had safety concerns (neutropenia, mast cell depletion).
Celldex reported a Q3 2026 net loss of $75.56M and filed a universal shelf registration, signaling potential future dilution to fund operations and the BLA submission.
The CSU market has entrenched competition from Xolair (omalizumab) and potential future competition from Novartis' ligelizumab, which may limit barzolvolimab's commercial uptake.

Upcoming Catalysts

  • BLA submission to FDA for CSU (planned 2027, no specific date)
  • Phase 2 atopic dermatitis topline data readout (date not specified)
  • Phase 3 ColdU/SD topline data readout (date not specified)
  • Additional Phase 3 CSU 52-week data presentations at medical conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Celldex Therapeutics, Inc. 8-K CLDX ·Originating report

Sources · 12

Hover a chip for the title
1 markets.businessinsider.com2 morningstar.com3 fiercebiotech.com4 morningstar.com5 msn.com6 nasdaq.com7 markets.financialcontent.com8 markets.financialcontent.com9 seekingalpha.com10 fiercebiotech.com11 fiercebiotech.com12 empr.com